Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Trial Profile

Multicenter study phase IIb randomized, blind, controlled with Placebo in search of doses to assess efficacy, safety and tolerability of two dose Subcutaneas IPP-201101 more medication of base, versus Placebo more basic medication in patients with Systemic Lupus Erythematosus (SLE).

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors ImmuPharma
  • Most Recent Events

    • 28 Jan 2013 Results have been published in Annals of the Rheumatic Diseases according to an ImmuPharma media release.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 Nov 2012 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top